QurAlis, a biotechnology startup based in Cambridge, MA, has raised $88 million in a Series B funding round. The Funding was led by Dolby Family Ventures and EQT Life Sciences, with participation from Inkef, Droia Ventures, Mission Bay Capital, Mitsui & Co. Global Investment Ltd., Dementia Discovery Fund (DDF), Mission BioCapital, LS Polaris Innovation, ALS Investment Fund. They develop precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. The company aims to tackle specific disease-causing mechanisms to develop therapies. These therapies can significantly impact the lives of ALS patients and their families.

QurAlis discover precision therapeutics for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. ALS is a terminal disease that causes muscle paralysis through degeneration of the motor system, and there is currently no cure.

QurAlis is taking a unique approach to tackling ALS by digging deep into the root causes of the multiple sub-forms of the disease. The company's programs focus on developing therapies targeting disease-causing mechanisms. This precision approach has the potential to make a significant impact on the lives of ALS patients and their families.

The Funding will be used to advance QurAlis' pipeline of therapeutics for ALS. Furthermore, it includes both small molecule and gene therapy approaches. QurAlis has a team of world-class scientists and researchers working tirelessly to develop innovative treatments for ALS.

Visit us for the latest Funding round: https://founderlodge.com/round/QurAlis-raises-88000000-Series-B-2023-03-10-Kasper-Roet-MTA2MDg.